To include your compound in the COVID-19 Resource Center, submit it here.

Amgen, AbbVie settle Humira biosimilar dispute

Amgen Inc. (NASDAQ:AMGN) has agreed to delay until early 2023 the U.S. launch of its biosimilar version of autoimmune drug Humira adalimumab from AbbVie Inc. (NYSE:ABBV) in a deal announced Thursday that resolves patent litigation between the companies. Amgen will pay AbbVie undisclosed royalties in exchange for a non-exclusive license to Humira patents and rights to launch its biosimilar in

Read the full 601 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE